Daffodil Drugs Profile
Key Indicators
- Authorised Capital ₹ 6.50 M
as on 10-12-2024
- Paid Up Capital ₹ 6.30 M
as on 10-12-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.76 Cr
as on 10-12-2024
- Revenue 39.86%
(FY 2022)
- Profit 39.08%
(FY 2022)
- Ebitda 29.36%
(FY 2022)
- Net Worth 29.80%
(FY 2022)
- Total Assets 53.49%
(FY 2022)
About Daffodil Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.50 M and a paid-up capital of Rs 6.30 M.
The company currently has active open charges totaling ₹9.76 Cr.
Prodyot Mazumder and Madhumita Majumdar serve as directors at the Company.
- CIN/LLPIN
U51909WB2008PTC127083
- Company No.
127083
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jul 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Social Media-
Who are the key members and board of directors at Daffodil Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prodyot Mazumder  | Director | 02-Jul-2008 | Current |
| Madhumita Majumdar | Director | 02-Jul-2008 | Current |
Financial Performance of Daffodil Drugs.
Daffodil Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 39.86% increase. The company also saw a substantial improvement in profitability, with a 39.08% increase in profit. The company's net worth Soared by an impressive increase of 29.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daffodil Drugs?
In 2022, Daffodil Drugs had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 02 Mar 2022 | ₹1.10 Cr | Open |
Indian Bank Creation Date: 02 Mar 2022 | ₹1.00 Cr | Open |
Indian Bank Creation Date: 30 Nov 2021 | ₹6.81 M | Open |
How Many Employees Work at Daffodil Drugs?
Daffodil Drugs has a workforce of 69 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daffodil Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daffodil Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
